Press Releases from Intas Biopharmaceuticals Limited (6 total)
Intas Biopharmaceuticals win GOLD award for Quality Excellence
Ahmedabad, January 27, 2010: Intas Biopharmaceuticals Limited, India’s premier biopharmaceutical organization, has received GOLD Award for Quality Excellence in the category of Formulations Unit. The award was conferred by Indian Drug Manufacturer’s Association (IDMA) on January 16, 2010 during its Annual Day Celebrations. The awards were presented by B. S. Jharwar, Chairman, National Pharmaceutical Pricing Authority (NPPA) and Devender Choudhary, Joint Secretary, Department of Pharmaceuticals. From company’s end, Mr. Hitesh…
Awareness for “Growth Factors” in India: A social initiative of Intas Biopha …
Cancer, being one of the most dreadful diseases in recent times, has generated a necessity to increase the awareness in the society and medical fraternity. The Oncology market in India has witnessed sharp growth in recent years and it has become a requisite for dedicated Oncology companies like Intas Biopharmaceuticals Limited (IBPL) to play a leading role in increasing the awareness of scientific knowledge and information related to Research &…
INTAS BIOPHARMACEUTICALS ACQUIRES US–BASED BPD INC
India’s leading biopharmaceutical company, Intas Biopharmaceuticals Limited (IBPL) has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc.), based in Poway, California. With acquisition process underway, both companies are actively pursuing plans to work closely towards fulfillment of common business objectives in the area of Contract Research and Manufacturing Services (CRAMS). With agreement in the final stages of completion, the financials has been undisclosed and will be accordingly announced…
Intas Biopharma to market lung cancer drug GEFITINIB in India
Intas Biopharmaceuticals Limited is all set to market Lung Cancer drug, GEFITINIB, under brand name “GEFFY”, in Indian market. In line with company’s sales strategy to market novel targeted therapies, Intas Biopharmaceuticals will market GEFFY for treatment of Lung cancer especially non-small cell lung cancer (NSCLC). The new drug GEFFY is a class of anti-cancer medications called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It works by blocking the…
Intas plans Filgrastim launch in North America, Europe
Intas Biopharma is a part of Cooperation between three continents for Biosimilar GCSF
Ahmedabad, May 5, 2008: INTAS BIOPHARMACEUTICALS LIMITED (IBPL) signed business agreement with Canada–based APOTEX INC. for co-development and supply of its Filgrastim brand, Neukine® in North America (US and Canada). European pharmaceutical major Kwizda Pharma, who is working with IBPL to develop G-CSF for the European market, has transferred all of its rights in IBPL’s G-CSF to Apotex.…
INTAS BIOPHARMA & KWIZDA COMPLETE PHASE I CLINICAL TRIAL OF NEUKINE® IN EUROPE
Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of NEUKINE®, biosimilar form of recombinant GCSF. As per results of study conducted by European counterpart, NEUKINE®, IBPL’s registered trademark for Filgrastim, is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. Neukine® promotes growth of white blood cells, which help to fight infections after cancer…
